Codexis, Inc.  

(Public, NASDAQ:CDXS)   Watch this stock  
Find more results for CDXS
4.95
-0.10 (-1.98%)
Dec 9 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.85 - 5.05
52 week 2.93 - 5.25
Open 5.00
Vol / Avg. 89,517.00/107,558.00
Mkt cap 208.25M
P/E     -
Div/yield     -
EPS -0.14
Shares 41.22M
Beta -0.95
Inst. own 65%
Mar 1, 2017
Q4 2016 Codexis Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Nov 16, 2016
Codexis Inc at Craig-Hallum Alpha Select Conference
Nov 10, 2016
Q3 2016 Codexis Inc Earnings Call
Nov 8, 2016
Q3 2016 Codexis Inc Earnings Call
Nov 8, 2016
Q3 2016 Codexis Inc Earnings Release
Sep 12, 2016
Codexis Inc at Rodman & Renshaw Global Investment Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin 9.66% -18.13%
Operating margin 9.54% -18.59%
EBITD margin - -10.52%
Return on average assets 15.30% -16.34%
Return on average equity 27.11% -30.82%
Employees 91 -
CDP Score - -

Address

200 Penobscot Dr
REDWOOD CITY, CA 94063-4718
United States - Map
+1-650-4218100 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Codexis, Inc. is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company's CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale. The Company's pharmaceutical products include enzymes, pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and Codex Biocatalyst Panels and Kits. The fine chemicals market consists of several market verticals, including food and food ingredients, animal feed, flavors and fragrances, and agricultural chemicals. The Company also uses its technology to develop an early stage, enzyme therapeutic product candidate for the treatment of phenylketonuria (PKU) in humans through oral administration.

Officers and directors

Bernard J. Kelley Chairman of the Board
Age: 73
Bio & Compensation  - Reuters
John J. Nicols President, Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Gordon T. Sangster Chief Financial Officer, Senior Vice President
Age: 61
Bio & Compensation  - Reuters
Douglas T. Sheehy J.D. Executive Vice President, Chief Administrative Officer, General Counsel, Secretary
Age: 48
Bio & Compensation  - Reuters
Michael Douglas Arthur Aldridge Senior Vice President - Corporate & Strategic Development
Bio & Compensation  - Reuters
James Lalonde Senior Vice President, Research & Development
Age: 54
Bio & Compensation  - Reuters
Thomas R. Baruch J.D. Chairman Emeritus
Bio & Compensation  - Reuters
Pam P. Cheng Director
Age: 45
Bio & Compensation  - Reuters
Kathleen Sereda Glaub Director
Bio & Compensation  - Reuters
Patrick Y. Yang Director
Bio & Compensation  - Reuters